David Hui Shao, Ph.D., MBA, CFA, CPA

Hui (David) Shao, PhD, MBA, CFA, CPA, brings over 20 years of experience in multinational corporate strategy and global operations, with a rare combination of biotechnology and finance expertise. He began his career as a Principal Scientist at Roche, later moving to Wall Street in New York, where he focused on biopharma investment and hedge fund management. He subsequently served as CFO and CEO of biopharmaceutical companies, overseeing the full value chain from R&D and manufacturing to commercialization, and led an organization of approximately 700 employees generating about $100 million in annual revenue.

Dr. Shao has guided multiple companies to public listings on NASDAQ and the NYSE, establishing cross-border capital market connectivity across the U.S., China, and Hong Kong. His areas of expertise include corporate restructuring, biologics commercialization, pipeline strategy optimization, cross-border business development and licensing, equity and financing strategy, and financial management systems.

He holds an MBA in Finance and Accounting from NYU Stern School of Business and a PhD in Bioorganic Chemistry from the University of California, San Diego.

 

邵辉（David）博士、MBA、CFA、CPA，拥有逾20年跨国企业战略与全球运营经验，兼具生物医药与金融双重背景。他的职业生涯始于罗氏制药担任首席科学家，随后赴纽约华尔街从事生物医药投资及对冲基金管理。其后历任多家生物制药企业CFO及CEO，全面负责从研发、生产到商业化的全价值链运营，并曾带领约700人的团队实现约1亿美元年销售收入。

邵博士曾推动多家公司在纳斯达克及纽约证券交易所上市，打通美国、中国与香港三地资本市场的跨境联动通道。其专长涵盖公司重组、生物制剂商业化、研发管线战略优化、跨境业务拓展与授权合作、股权与融资策略设计，以及财务管理体系建设。

他拥有纽约大学斯特恩商学院（NYU Stern）金融与会计MBA学位，以及加州大学圣地亚哥分校（UC San Diego）生物有机化学博士学位。